EU inks third contract with BioNTech-Pfizer for new 1.8 billion vaccine doses
The delivery is guaranteed from the start of the supply in 2022Europost , Brussels
The Commission signed on Thursday a third contract with the pharmaceutical companies BioNTech and Pfizer. According to it, 1.8 billion doses Covid-19 vaccines, known as Comirnaty, will be reserved on behalf of all EU27 for end-2021 to 2023. It will allow for the purchase of 900 million doses of the current vaccine and of such adapted to variants, with an option for an extra 900 million jabs.
As the EU executive reveals, the vaccine production is based in the EU and essential components are sourced from the EU, under this contract. It requires as well that from the start of the supply in 2022, the delivery to the EU is guaranteed.
“Thanks to the well-established cooperation with the companies under the current contracts and arrangements put in place, timely deliveries of the doses are ensured. The possibility for Member States to resell or donate doses to countries in need outside the EU or through the COVAX Facility has been reinforced, contributing to a global and fair access to the vaccine across the world. This new contract will strengthen the EU vaccine production capacity thus allowing to serve other markets across the world, ” the Commission announced.
With our signature, the new contract is now in force, which is good news for our long term fight to protect European citizens against the virus and its variants, EC President Ursula von der Leyen underlined. She added that potential contracts with other manufacturers will follow the same model.